Physician profile
Kaitlyn Smith
NPI 1245798032
$9,899.78
in general payments reported to CMS, 2019-2025
30 companies · $2,806 in 2025
The $2,806 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,634 · 2022: $1,820 · 2023: $1,557 · 2024: $2,083 · 2025: $2,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,273 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,272.68 |
| Education | $173.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.46 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $789.88 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $683.10 | 2021-2025 | |
| Leo Pharma INC. | $653.04 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $649.37 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $607.71 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $557.96 | 2021-2025 | Blu-U, Odomzo, Winlevi |
| Ucb, INC. | $524.56 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $523.19 | 2021 | |
| Incyte Corporation | $517.68 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $358.41 | 2023-2025 | |
| Pfizer INC. | $317.94 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $259.23 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Amgen INC. | $247.05 | 2021-2025 | Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $235.84 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $193.54 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Organon LLC | $175.28 | 2023-2025 | Hadlima, Vtama |
| Janssen Scientific Affairs, LLC | $161.84 | 2021-2022 | |
| Almirall LLC | $116.56 | 2023-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $87.84 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $73.33 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $44.88 | 2021 | |
| Verrica Pharmaceuticals INC. | $28.15 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2025 | Spevigo |
| Epi Health, LLC | $19.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.07 | 2024 | Sotyktu |
| Botanix Sb INC | $16.51 | 2025 | Sofdra |
| Fidia Pharma USA INC. | $13.79 | 2025 | Hymovis, Triluron |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2023 | Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.